Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Introduction
This study aimed to determine the efficacy of combining plasma phosphorylated tau (p‐tau)181, amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), and apolipoprotein E (APOE) genotypes for detecting positive amyloid positron emission tomography (PET), which is little known in the Asian population, in two independent cohorts.
Meth...
Alternative Titles
Full title
Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3c9c3ba984d24b738b07ade03e49a80b
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3c9c3ba984d24b738b07ade03e49a80b
Other Identifiers
ISSN
2352-8729
E-ISSN
2352-8729
DOI
10.1002/dad2.12502
